INVITATION ONLY: Lamivudine study for Rett syndrome – Brazil

Status: Enrolling by invitationStudy: Lamivudine as a novel clinical effort for Rett syndrome
Registry number: NCT07640503
Location: GenClinics, Fortaleza, Ceará, Brazil
Participants: Females aged 2 years and older

What is being studied?
This small before-and-after study is examining the safety and possible clinical and biological effects of oral lamivudine in ten people with Rett syndrome. Researchers will assess symptoms, function, quality of life, seizures and laboratory biomarkers.

Lamivudine is normally an antiviral medicine. Its use for Rett syndrome is investigational and enrolment is currently by invitation.

Official study record: https://clinicaltrials.gov/study/NCT07640503

Information checked 3 September 2026. Effectiveness for Rett syndrome has not been established. Do not start or change medication because of this post; contact the investigators and the person’s doctor.